



ABOUT THERAVITAE



TheraVitae is a biotechnology company with the mission of developing, mass-producing, and commercializing adult stem cell therapies for incurable diseases, specifically cardiovascular disorders using blood-borne Angiogenic Cell Precursors (ACPs). The Company has already introduced stem cell-based treatments to the Thai market this year, bringing previously unimaginable hope to patients suffering from severe cardiac diseases. The company is positioned at the forefront of cellular therapy, an emerging area of therapeutics for severe disorders for which appropriate treatments do not exist.

A semi-automated robotic production line (the first of its kind) will be initiated by the end of 2009 in both Israel and Thailand. This means our company will be able to process several hundred batches of adult stem cells per month in each location. This will enable our company to lower our costs and pass on the savings to our patients.

Our company currently offers its novel therapy to patients suffering from advanced angina pectoris who are willing to undergo the only treatment with potential to alleviate this otherwise incurable disease. Despite major progress made in the numerous drugs and invasive procedures that these patients are treated with, no cure is available for a large portion of those who are suffering from clogged coronary vessels. As the patients' conditions continue to deteriorate, they are often condemned to live the rest of their lives in armchairs or are bedridden.

Thanks to its devoted, professional, and highly experienced scientific and medical teams, TheraVitae initiated a clinical trial of its first product, VesCell, to treat severe angina pectoris. This treatment has thus far been proven safe and signs of efficacy have been observed.

TheraVitae is now expanding its VesCell treatment platform to include additional diseases such as coronary artery disease, congestive heart failure, and cardiomyopathy.

TheraVitae has developed a new generation of cellular medicine that safely harnesses the power of the patient's own body to heal itself by using ACPs, a subset of adult stem cells. Similar to other stem cells, these cells normally develop in the bone marrow. However, scarce numbers of



ABOUT THERAVITAE



ACPs are released continuously in the peripheral blood although they never exceed 0.1% of the total amount of white blood cells. By using sophisticated tissue culture techniques, the company's scientists have developed a process whereby ACPs are obtained from blood rather than from bone marrow and expanded ex vivo to obtain a product to treat severe heart disorders. This treatment shows similar, if not greater promise than its bone marrow counterpart, which, itself, has already been used in dozens of severely ill cardiac patients with high rates of success. The skill and experience of its scientists in cellular therapy and related fields have enabled TheraVitaе to pioneer this proprietary process. A US patent was filed in June 2004. The Company's scientists understand the crucial importance of generating a well-controlled cell-product. By using blood and not bone marrow as the "raw material" the product's safety as well as its efficacy can be improved. The ability to "tame" living cells and manufacture a reproducible product is corroborated by the vast clinical and scientific experience of Prof. Alexander Battler, the Company's Chief Medical Officer and one of the few cardiologists in the world to have successfully used cell therapies in patients.

Available non-cellular therapeutic modalities, even the most sophisticated re-vascularization techniques, address only disease occurring in relatively large vessels. TheraVitaе's therapy treats the problem occurring in small vessels, thus targeting a different pathological angle of the disease altogether. This minimally invasive "micro-revascularization" technology is synergistic with existing "macro-revascularization" treatments such as angioplasty and coronary artery bypass grafting.

Hundreds of cardiac patients all over the world have already been treated safely and effectively with angiogenetic progenitor cells. Clinical trials using the same type of cells (obtained from bone marrow rather than blood) have already proven successful in Germany and Japan. Furthermore, in May, 2004 a team of surgeons from the University of Pittsburgh, led by Dr. Amit Patel, proved the efficacy of a similar therapy in a controlled, randomized trial.

TheraVitaе's strength also stems from the experience and skill of its management team. The team effectively combines talent and expertise in science and medicine as well as in business and product development.



ABOUT THERAVITAE



Mr. Robert Clark founder of Theravitaе is an experienced entrepreneur and investor in the high-tech industry in Southeast Asia. Prof. Alexander Battler, Chief Medical Officer, one of the world's most eminent cardiologists, is the Director of Cardiology Services at Rabin Medical Center in Israel. Prof. Michael Belkin MA,MD, Chief clinical consultant, Fox Chair of Ophthalmology and Director, Goldschleger Eye Research Institute, Tel Aviv University. Research and development activities are led by Dr. Yael Porat, an immunologist with a strong background in cell therapy, and former manager of the Biological Method Development Lab at Teva Pharmaceuticals. Dr. Adina Belleli and Dr. Ina Sarel Directors of Research and Development, Dr. Thein Htut, Medical Director and General Manager, has many years of experience in the career of marketing and business development. He has worked as a Regional Manager, Biomedical Divisional Manager, and Medical Advisor with well known medical companies in Thailand as well as medical product manufacturers from the USA.

TheraVitaе has a 6000 square feet research and manufacturing facility at Kiryat Weizmann, Israel and 3000 square feet of office space in Bangkok, Thailand. The Israeli facility includes a state of the art GMP cell-processing center. The company currently has 30 employees in its two locations, all professionals in biotech product development, medicine and marketing.

TheraVitaе commenced treating private patients on January 3, 2005, after obtaining positive results from its focused clinical trial initiated in August 2004 at Siriraj Hospital. The principal investigator of the trial is Professor Damras Tresukosol who is collaborating with Prof. Battler and Prof. Suphachai Chaitiraphan, the Chairman of the ASEAN Heart. Professor Damras and Professor Suphachai are currently using this novel therapy on private patients at Chao Phya Hospital in Bangkok, Thailand. Bangkok Heart Hospital, Phyathai2 Hospital and Praram9 Hospital in Bangkok are also using this novel therapy. As productivity and demand increase, the company will introduce this therapy to other hospitals throughout Thailand.